ArticleNature genetics2020
DNA methylation disruption reshapes the hematopoietic differentiation landscape.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers.
0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
151 citing papers in PubMed, 255 citations in OpenAlex.
- A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.Seminars in hematology · 2021Trial
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Trained immunity links hematopoietic stem cell aging to aging-associated inflammation.Nature aging · 2026Article
- The Evolution of Polyclonal Competition in Aging Hematopoiesis.Cancer discovery · 2026Article
- Disruption of methionine metabolism drives erythroid cell fate reprogramming by remodeling the H3K4me3 landscape.The Journal of clinical investigation · 2026Article
- TET2 as a Context-Dependent Epigenetic Integrator in Clonal Hematopoiesis, Inflammation, Cancer, and Immunotherapy.Cell biochemistry and function · 2026Review
- Quantitative molecular cartography of emergency myelopoiesis reveals conserved modules of hematopoietic activation.Cell stem cell · 2026Article
- Lineage tracing from cellular heritage to disease destiny.Nature genetics · 2026Review
- Aging mechanisms and rejuvenation strategies for hematopoietic stem cells.Genome biology · 2026Review
- Article
- Aberrant Kupffer-like differentiation of hematopoietic stem cell is critical for the MDS pathogenesis in Setd2-deficient mice.Cell death and differentiation · 2026Article
- DNMT3A R882H Is Not Required for Disease Maintenance in Primary Human AML but Is Associated with Increased Leukemia Stem Cell Frequency.Cancer discovery · 2026Article
- Review
- Cancer-Like Fragmentomic Characteristics of Somatic Variants in Cell-Free DNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TET2 in epigenetic control of immune cells: Implications for inflammatory responses and age-related pathologies.The Journal of biological chemistry · 2026Review
- Glucocorticoids and cell fate in the developing brain: Neuroendocrine mechanisms shaping developmental trajectories.Journal of neuroendocrinology · 2026Review
- Accurate and reliable detection of clonal hematopoiesis in plasma cell-free DNA.Blood advances · 2026Article
- TET2: a critical regulatory hub with broad therapeutic implications across human diseases.Frontiers in immunology · 2026Review
- DNA methylation as a new frontier in treating fear-related disorders: A need for careful evaluation.World journal of psychiatry · 2025Article
- DNA Methylation Reflects Cis-Genetic Differentiation Across the European Crow Hybrid Zone.Molecular ecology · 2025Article
91 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 4 institutions in 1 country.
Franco Izzo *New York Genome Center, New York, NY, USA.
Stanley C Lee *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7110-2416
Asaf PoranMeyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Ronan ChaligneNew York Genome Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4332-3291
Federico GaitiNew York Genome Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5111-8816
Baptiste GrossNew York Genome Center, New York, NY, USA.
Rekha R MuraliNew York Genome Center, New York, NY, USA.
Sunil D DeochandNew York Genome Center, New York, NY, USA.
Chelston AngNew York Genome Center, New York, NY, USA.
Philippa Wyndham JonesNew York Genome Center, New York, NY, USA.
Anna S NamNew York Genome Center, New York, NY, USA.
Kyu-Tae KimNew York Genome Center, New York, NY, USA.
Steven Kothen-HillNew York Genome Center, New York, NY, USA.
Rafael C SchulmanNew York Genome Center, New York, NY, USA.
Michelle KiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Priscillia LhoumaudNew York University Langone Health, New York, NY, USA.
Jane A SkokNew York University Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-4145-1516
Aaron D VinyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-7039-0110
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ephraim KenigsbergDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3907-6171
Dan A LandauNew York Genome Center, New York, NY, USA. dlandau@nygenome.org.ORCID http://orcid.org/0000-0003-2346-9541
Cornell University · USMemorial Sloan Kettering Cancer Center · USNYU Langone Health · USIcahn School of Medicine at Mount Sinai · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MNuclear organization and its role in gene regulationR35GM122515 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2017 to 2026
$7.1MShapeshifters in Cancer: Defining the Fundamental Forces of Leukemia EvolutionDP2CA239065 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN · 2018 to 2018
$2.5MThe role of DNA methylation modifiers in shaping the hematopoietic differentiation topologyR01HL145283 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LANDAU, DAN · 2019 to 2022
$2.0MRole of the Cohesin complex in normal and malignant hematopoiesisK08CA215317 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VINY, AARON D · 2018 to 2022
$1.3MDefining novel genetic dependencies in spliceosome mutant leukemiaR00CA218896 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STANLEY CHUN-WEI · 2020 to 2022
$747kNCI NIH HHS DP2 CA239065NCI NIH HHS K08 CA215317NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA218896NHLBI NIH HHS R01 HL128239NHLBI NIH HHS R01 HL145283NIGMS NIH HHS R35 GM122515
Abstract
Mutations in genes involved in DNA methylation (DNAme; for example, TET2 and DNMT3A) are frequently observed in hematological malignancies
Indexed as
AnimalsCell DifferentiationDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationHematopoiesisHematopoietic Stem CellsHumansMaleMiceMice, TransgenicMutationTranscription, GeneticTranscriptomeDNA-Binding ProteinsDNA (Cytosine-5-)-Methyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.